Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB01097_DB01285_nanopub.RAcP33SImL4YhVLPhKdeqgjGN50z02O4a5sqxSmPKSiLc#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB01097_DB01285 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB01097_DB01285 label "DDI between Leflunomide and Corticotropin - Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy. [drugbank_resource:DB01097_DB01285]" assertion.
- drugbank_resource:DB01097_DB01285 identifier "drugbank_resource:DB01097_DB01285" assertion.
- drugbank_resource:DB01097_DB01285 title "DDI between Leflunomide and Corticotropin - Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy." assertion.
- drugbank:DB01285 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01097_DB01285 assertion.
- drugbank:DB01097 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01097_DB01285 assertion.